Subscribe to RSS
DOI: 10.1055/s-2004-831344
© Georg Thieme Verlag Stuttgart · New York
Helicobacter-pylori Infektion - ein Update 2004
Helicobacter pylori infection - update for the clinician 2004Publication History
eingereicht: 6.5.2004
akzeptiert: 9.8.2004
Publication Date:
16 August 2004 (online)

Auch im Jahr 2004 bleibt die Beschäftigung mit der Helicobacter-pylori(H.p.)-Infektion eine spannende Herausforderung für Klinik und Grundlagenforschung [46]. Die H.p.-Therapie zur Heilung der peptischen Ulkuskrankheit ist zwar allgemein akzeptiert, allerdings lässt die letzte Konsequenz der Umsetzung dieser Behandlung in der Praxis immer noch Wünsche offen. Die klinische Diskussion dreht sich weiterhin um Indikationsstellungen zur Behandlung der H.p.-Infektion, wenn noch keine Komplikationen eingetreten sind. Aktuell sind vor allem Fragen, ob Patienten mit dyspeptischen Beschwerden bei H.p.-positiver Gastritis von dieser Therapie profitieren, ob die Behandlung der Infektion vor Schäden durch nicht-steroidale Antirheumatika (NSAR) schützt, und nicht zuletzt, ob eine Prävention des Magenkarzinoms durch H.p.-Eradikation erreicht werden kann.
Literatur
- 1
Birkner B, Hotz J, Labenz J. et al .
Kurzgefasste Leitlinie zum Dyspepsie-Management.
Dtsch Med Wochenschr.
2004;
129 (18)
1032-1034
MissingFormLabel
- 2
Blaser M J.
Hypothesis: the changing relationship of H.p. and humans: implications for health
and disease.
J Infect Dis.
1999;
179
1523-1530
MissingFormLabel
- 3
Brenner H, Arndt V, Stegmaier C. et al .
Is H.p. infection a necessary condition for noncardia gastric cancer?.
Am J Epidemiol.
2004;
159
252-258
MissingFormLabel
- 4
Chan F K, Chung S C, Suen B Y. et al .
Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter
pylori infection who are taking low-dose aspirin or naproxen.
N Engl J Med.
2001;
344
967-973
MissingFormLabel
- 5
Chan F K, To K F, Wu J C. et al .
Eradication of H.p. and risk of peptic ulcers in patients starting long-term
treatment with non-steroidal anti-inflammatory drugs: a randomised trial.
Lancet.
2002;
359
9-13
MissingFormLabel
- 6
Chiba N, Veldhuyzen Van Zanten S JO, Escobedo S. et al .
Economic evaluation of H.p. eradication in the CADET-Hp randomized controlled
trial of H.p. positive primary care patients with uninvestigated dyspepsia.
Aliment Pharmacol Ther.
2004;
19
349-358
MissingFormLabel
- 7
Chiba N, Veldhuyzen Van Zanten S JO, Sinclair P. et al .
Treating H.p. infection in primary care patients with uninvestigated dyspepsis:
the Canadian adult dyspepsia empiric treatment - H.p. positive (CADET-Hp) randomised
controlled trial.
Brit Med J.
2002;
324
1-7
MissingFormLabel
- 8
Churin Y, Al-Ghoul L, Kepp O. et al .
Helicobacter pylori CagA protein targets the c-Met receptor and enhances the
motogenic response.
J Cell Biol.
2003;
28 (161)
249-255
MissingFormLabel
- 9
Dore M P, Osato M S, Malaty H M. et al .
Characterization of a culture method to recover Helicobacter pylori from the
feces of infected patients.
Helicobacter.
2000;
5
165-168
MissingFormLabel
- 10
El Omar E M, Rabkin C S, Gammon M D. et al .
Increased risk of noncardia gastric cancer associated with proinflammatory cytokine
gene polymorphisms.
Gastroenterology.
2003;
124
1193-201
MissingFormLabel
- 11
Fischbach W, Goebeler-Kolve M E, Dragosics B. et al .
Long term outcome of patients with gastric marginal zone B cell lymphoma of
mucosa associated lymphoid tissue (MALT) following exclusive Helicobacter pylori
eradication therapy: experience from a large prospective series.
Gut.
2004;
53
34-37
MissingFormLabel
- 12
Gisbert J, Calvet X, Bujanda L. et al .
’Rescue’ therapy with rifabutin after multiple Helicobacter pylori treatment
failures.
Helicobacter.
2003;
8
90-94
MissingFormLabel
- 13
Glupczynski Y, Megraud F, Lopez-Brea M. et al .
European multicentre survey of in vitro antimicrobial resistance in Helicobacter
pylori.
Eur J Clin Microbiol Infect Dis.
2001;
20
820-823
MissingFormLabel
- 14
Glynn M K, Friedman C R, Gold B D. et al .
Seroincidence of Helicobacter pylori infection in a cohort of rural Bolivian
children: acquisition and analysis of possible risk factors.
Clin Infect Dis.
2002;
35
1059-1065
MissingFormLabel
- 15
Granquist A, Bredberg A, Sveger T. et al .
A longitudinal cohort study on the prevalence of Helicobacter pylori antibodies
in Swedish children and adolescents.
Acta Paediatr.
2002;
91
636-640
MissingFormLabel
- 16
Grimm W, Fischbach W.
Helicobacter pylori infection in children and juveniles: an epidemiological
study on prevalence, socio-economic factors and symptoms.
Dtsch Med Wochenschr.
2003;
128
1878-1883
MissingFormLabel
- 17
Heuberger F, Pantoflickowa D, Gassner M. et al .
H.p. infection in Swiss adolescents. Prevalence and risk factors.
Eur J Gastroenterol Hepatol.
2003;
15
179-183
MissingFormLabel
- 18
Huang J, Hunt R.
The importance of clarithromycin dose in the management of Helicobacter pylori
infection: a meta-analysis of triple therapies with a proton pump inhibitor,
clarithromycin and amoxicillin or metronidazole.
Aliment Pharmacol Ther.
1999;
13
857-64
MissingFormLabel
- 19
Kist M, Glocker E.
Helicobacter pylori Infektionen: ResiNet - eine bundesweite Sentinelstudie zur
Resistenzentwicklung.
Epidemiol Bull.
2003;
47
389-391
MissingFormLabel
- 20
Klotz U, Schwab M, Treiber G.
CYP2C19 Polymorphism and Proton Pump Inhibitors.
Basic Clin Pharmacol Toxicol.
2004;
95
2-8
MissingFormLabel
- 21
Kuipers E J, Nelis G F, Klinkenberg-Knol E C. et al .
Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated
with long term omeprazole reverses gastritis without exacerbation of reflux
disease: results of a randomised controlled trial.
Gut.
2004;
53
12-20
MissingFormLabel
- 22
Labenz J, Blum A L, Bolten W W. et al .
Primary prevention of diclofenac associated ulcers and dyspepsia by omeprazole
or triple therapy in H.p. positive patients: a randomised, double blind, placebo
controlled, clinical trial.
Gut.
2002;
51
329-335
MissingFormLabel
- 23
Lai K C, Lam S K, Chu K M. et al .
Lansoprazole for the prevention of recurrences of ulcer complications from long-term
low-dose aspirin use.
N Engl J Med.
2002;
346
2033-2038
MissingFormLabel
- 24
Leodolter A, Dominguez-Munoz J E, Von Arnim U. et al .
Validity of a modified 13C-urea breath test for pre- and posttreatment diagnosis
of Helicobacter pylori infection in the routine clinical setting.
Am J Gastroenterol.
1999;
94
2100-2104
MissingFormLabel
- 25
Leodolter A, Malfertheiner P.
Aktuelle diagnostische Methoden zum Nachweis der Helicobacter-pylori-Infektion.
Dtsch Med Wochenschr.
2001;
126
207-209
MissingFormLabel
- 26
Leodolter A, Wolle K, Malfertheiner P.
Current standards in the diagnosis of H. pylori infection.
Dig Dis.
2001;
19
116-122
MissingFormLabel
- 27
Leodolter A, Peitz U, Ebert M P. et al .
Comparison of two enzyme immunoassays for the assessment of Helicobacter pylori
status in stool specimens after eradication therapy.
Am J Gastroenterol.
2002;
97
1682-1686
MissingFormLabel
- 28
Leodolter A, Vaira D, Bazzoli F. et al .
European multicentre validation trial of two new non-invasive tests for the
detection of Helicobacter pylori antibodies: urine-based ELISA and rapid urine
test.
Aliment Pharmacol Ther.
2003;
18
927-931
MissingFormLabel
- 29
Leodolter A, Wolle K, Peitz U. et al .
Evaluation of a near-patient fecal antigen test for the assessment of Helicobacter
pylori status.
Diagn Microbiol Infect Dis.
2004;
48
145-147
MissingFormLabel
- 30
Malfertheiner P.
H.p. eradication does not exacerbate gastro-oesophageal reflux disease.
Gut.
2004;
53
312-313
MissingFormLabel
- 31
Malfertheiner P, Megraud F, O’Morain C. et al .
Current concepts in the management of Helicobacter pylori infection - The Maastricht
2 - 2000 Consensus Report.
Aliment Pharmacol Ther.
2002;
16
167-180
MissingFormLabel
- 32
Malfertheiner P, Mössner J, Fischbach W. et al .
H.p. eradication is beneficial in the treatment of functional dyspepsia.
Aliment Pharmacol Ther.
2003;
15
615-625
MissingFormLabel
- 33
Malfertheiner P, Peitz U, Treiber G.
What constitutes failure for Helicobacter pylori eradication therapy?.
Can J Gastroenterol.
2003;
17 (Suppl B)
53B-57B
MissingFormLabel
- 34
Manes G, Menchise A, De Nucci C. et al .
Empirical prescribing for dyspepsia. randomised controlled trial of test and
treat versus omeprazole treatment.
Brit Med J.
2003;
326
1118
MissingFormLabel
- 35
Mc Coll K EL, Murray L S, Gillen D. et al .
Randomised trial of endoscopy with testing for Helicobacter pylori compared
with non-invasive H.p. testing alone in the management for dyspepsia.
Brit Med J.
2002;
324
999-1002
MissingFormLabel
- 36
Meining A G, Bayerdorffer E, Stolte M.
Helicobacter pylori gastritis of the gastric cancer phenotype in relatives of
gastric carcinoma patients.
Eur J Gastroenterol Hepatol.
1999;
11
717-720
MissingFormLabel
- 37
Melo E T, Lopes E P, Almeida J R, Albuquerque H F, Moura I M.
Seroprevalence of H. pylori antibodies in medical students and residents in
Recife, Brazil.
Clin Gastroenterol.
2003;
36
134-8
MissingFormLabel
- 38
Mitchell H M, Hu P, Chi Y. et al .
A low rate of reinfection following effective therapy against Helicobacter pylori
in a developing nation.
Gastroenterology.
1998;
114
256-261
MissingFormLabel
- 39
Nardone G, Morgner A.
Helicobacter pylori and gastric malignancies.
Helicobacter.
2003;
8,1
44-52
MissingFormLabel
- 40
Osato M S, Reddy R, Graham D Y.
Metronidazole and clarithromycin resistance amongst Helicobacter pylori isolates
from a large metropolitan hospital in the United States.
Int J Antimicrob Agents.
1999;
12
341-347
MissingFormLabel
- 41
Peitz U, Leodolter A, Wex T. et al .
Diagnostics of Helicobacter pylori infection in patients with peptic ulcer bleeding.
Z Gastroenterol.
2004;
42
141-146
MissingFormLabel
- 42
Raymond J, Kalach N, Bergeret M. et al .
Prevalence of Helicobacter pylori infection in children according to their age.
A retrospective study.
Arch Pediatr.
1998;
5
617-620
MissingFormLabel
- 43
Roma-Giannikou E, Karameris A, Balatsos B. et al .
Intrafamilial spread of Helicobacter pylori: a genetic analysis.
Helicobacter.
2003;
8
15-20
MissingFormLabel
- 44
Rothenbacher D, Brenner H.
Burden of H.p. and H.p.-related diseases in developed countries: recent developments
and future implications.
Microbes Infect.
2003;
5 (8)
693-703
MissingFormLabel
- 45
Schilling D, Demel A, Adamek H E. et al .
A negative rapid urease test is unreliable for exclusion of Helicobacter pylori
infection during acute phase of ulcer bleeding. A prospective case control study.
Dig Liver Dis.
2003;
35
217-221
MissingFormLabel
- 46
Suerbaum S, Michetti P.
Helicobacter pylori infection.
N Engl J Med.
2002;
347
1175-86
MissingFormLabel
- 47
Triantafillidis J K, Gikas A, Hyphantis T. et al .
Helicobacter pylori infection in hospital workers over a 5-year period. Correlation
with demographic and clinical parameters.
J Gastroenterol.
2002;
37
1005-1013
MissingFormLabel
- 48
Uemura N, Okamoto S, Yamamoto S. et al .
H.p. infection and the development of gastric cancer.
N Engl J Med.
2001;
345
784-789
MissingFormLabel
- 49
Wolle K, Leodolter A, Malfertheiner P. et al .
Antibiotic susceptibility of Helicobacter pylori in Germany: stable primary
resistance from 1995 to 2000.
J Med Microbiol.
2002;
51
705-9
MissingFormLabel
- 50
Wong B CY, Lam S K, Wong W M. et al .
H.p. eradication to prevent gastric cancer in a high-risk region of China.
J Amer Med Assoc.
2004;
291 (2)
187-194
MissingFormLabel
Prof. Dr. P. Malfertheiner
Klinik für Gastroenterologie, Hepatologie und Infektiologie der Otto-von-Guericke-Universität
Magdeburg
Leipziger Str. 44
39120 Magdeburg
Phone: 03 91-6 71 31 00
Fax: 03 91-6 71 31 05
Email: peter.malfertheiner@medizin.uni-magdeburg.de